What Olfen/Olfen 100 SR Treats: Main Uses and Benefits

Olfen/Olfen 100 SR is used to help manage symptoms across several key pain and inflammatory domains. The medication is used for conditions where symptoms involve discomfort, swelling, and stiffness. It is primarily applied across three main areas: to help ease the burden of chronic conditions like rheumatoid arthritis and osteoarthritis; for the supportive management of acute pain following physical injuries or certain medical procedures; and in specific situations, for addressing pain related to gynecological discomfort like primary dysmenorrhea.

This medication plays a role in managing symptoms when they become more noticeable. The medication is often applied in scenarios where symptoms create noticeable physiological strain and interfere with daily comfort. By easing these symptom clusters, the medicine helps patients cope more steadily with difficult episodes.

---

Quick Fact: Relief for Episodic Discomfort The medicine is commonly used to help manage symptoms associated with both long-term joint discomfort and acute episodes following injury.

Symptomatic Relief for Chronic Inflammatory Joint Conditions

The medicine is considered relevant in conditions characterized by periods of heightened symptoms, such as rheumatoid arthritis and osteoarthritis. It helps address symptom clusters that may become intense or disruptive in the joints, supporting the patient during difficult episodes by easing the overall symptom burden of discomfort, swelling, and stiffness associated with chronic disease.

Management of Acute Pain After Injuries and Procedures

The medication is applied when additional management of discomfort is appropriate for symptoms that create noticeable physiological strain. It is used in clinical settings that involve acute or unstable symptom patterns, such as those following a physical injury or certain medical procedures. It assists with maintaining functional stability by offering symptomatic relief that helps patients cope more steadily during episodes of heightened discomfort.

Assistance with Painful Gynecological Symptoms

Olfen/Olfen 100 SR is applicable within clinical settings that involve acute or disruptive symptom patterns, and is used for managing symptoms related to conditions like primary dysmenorrhea (painful menstrual periods). It is relevant for easing symptoms that interfere with daily comfort, contributing to improved day-to-day comfort during these symptomatic periods.

Regulatory References

1. NIH MedlinePlus overview of diclofenac

Olfen/Olfen 100 SR (diclofenac prolonged-release) eligibility is strictly defined by regulatory authorities based on pre-existing medical conditions, age, and physiological status.

The medicine is contraindicated in several specific populations:

Contraindicated Groups	Restriction Basis
Organ Failure	Severe cardiac failure (NYHA Class II–IV), severe renal failure, or severe hepatic failure.
GI Disease	Active gastrointestinal ulceration, bleeding, or perforation.
Allergy	Known hypersensitivity to diclofenac, aspirin, or other NSAIDs (NSAID-precipitated asthma, angioedema).
Vascular Disease	Established ischaemic heart disease, peripheral arterial disease, cerebrovascular disease, or following CABG surgery.
Pregnancy	The last trimester of pregnancy (after 30 weeks gestation).

Use is generally not recommended or restricted in:

• Children/Adolescents: Olfen 100 SR is not suitable for use in children and adolescents; safety and efficacy are not established for this specific prolonged-release formulation.
• Breastfeeding Mothers: Use is not recommended as the drug passes into breast milk in small amounts.
• High-Risk Patients: Individuals with mild-to-moderate organ impairment, high cardiovascular risk factors (e.g., uncontrolled hypertension, diabetes), or a prior history of GI bleeding require extreme caution and the use of the lowest effective dose for the shortest duration.

Interactions with other medicines and products

The official interaction profile for Diclofenac Sodium (Olfen/Olfen 100 SR) is defined by pharmacokinetic and pharmacodynamic constraints documented in regulatory labeling.

Contraindications and Exposure Modification Co-administration with other systemic NSAIDs or COX-2 selective inhibitors must be formally avoided due to the potential for additive adverse effects. Use with Aspirin (analgesic doses) is generally not recommended as it significantly increases the risk of serious gastrointestinal events. The medicine is contraindicated in the perioperative setting of CABG surgery.

Diclofenac is metabolized primarily by CYP2C9. Co-administration with CYP2C9 inhibitors, such as Voriconazole, is documented to significantly increase diclofenac exposure; Voriconazole specifically increased the plasma Cmax by 114% and AUC by 78%.

Risk-Based Interactions The concurrent use of Diclofenac with Anticoagulants, Antiplatelet Agents, SSRIs, or Oral Corticosteroids carries a documented increased risk of serious gastrointestinal bleeding. Use of Alcohol is also listed as a factor that increases this risk.

Combinations with ACE Inhibitors, ARBs, or Diuretics may diminish the therapeutic effect of these medicines and can lead to the deterioration of renal function. This risk is heightened in the elderly and those with volume depletion.

Inhibition of Prostaglandin Synthesis via COX Enzymes

Diclofenac exerts its primary mechanism by acting as a non-selective, reversible inhibitor of the Cyclooxygenase (COX) enzymes, specifically targeting both the COX-1 and COX-2 isoforms. This molecular interaction blocks the conversion of arachidonic acid into prostaglandins, which are chemical mediators that modulate inflammatory and nociceptive signaling pathways.

Modulation of Nociceptive and Vascular Pathways

By suppressing prostaglandin production, the drug reduces the sensitization of peripheral pain nerve endings (nociceptors), thereby reducing the transmission of sensitized nociceptive signals. Furthermore, the reduction of these mediators in local tissues constrains the prostaglandin-mediated increases in local vascular permeability.

Central Thermoregulatory Adjustment

The mechanistic effect extends centrally to the hypothalamus where the drug inhibits the prostaglandin E2 (PGE2 ) responsible for elevating the body's internal temperature set point. This action results in the adjustment of the hypothalamic temperature set point towards a lower baseline, which is the physiological basis for the observed modulation of core body temperature.

Instruction Map: How to use Olfen/Olfen 100 SR — Official Administration Guidelines

Olfen/Olfen 100 SR is a prolonged-release oral formulation of Diclofenac Sodium. Standard prescribing guidelines establish a standardized administration protocol focused on maintaining the integrity of the controlled-release dosage form and utilizing the lowest dose for the shortest period necessary.

---

Administration Scope

Feature	Detail
Route of Administration	The approved route is oral administration.
Dosing Schedule	The standard dosage for the prolonged-release form is 100 mg taken once per day. The total maximum daily intake from all diclofenac forms generally does not exceed 150 mg.
Timing in relation to meals	Administration is recommended to be with or after food and must be taken with liquid.
Age-group administration rules	The 100 mg prolonged-release unit is not suitable for children. For older adults, the lowest effective dosage is advised.
Missed-dose rules	If a dose is missed, it should be skipped, and the patient should continue with the next scheduled dose; doubling the dose is not indicated.
Special procedural conditions	The standard of care mandates that the lowest effective dose be used for the shortest duration necessary, with long-term use requiring periodic re-evaluation.

---

Instruction Classifications (High-Level)

Classification	Detail
Administration method type	Oral administration.
Frequency pattern	Once daily (q.d.).
Use-context constraints	The unit must not be chewed, crushed, or broken, as the integrity of the prolonged-release system must be maintained.

---

Resulting Procedural Structure

Official step sequence:

• The 100 mg prolonged-release unit is taken once per day.
• The unit must be swallowed whole with liquid.
• The dose is administered with or after food.
• The need for continued administration must be periodically re-evaluated.

Connection to the overall use protocol (2–4 sentences): The official administration protocol is defined by the once-daily schedule and the non-compensatory rule for missed doses, standardizing the temporal pattern of use. This structure centers on maintaining the integrity of the prolonged-release formulation, a key factor achieved by the instruction to administer the unit whole and undivided. This formalizes the application of the medicine as a structured regimen.

Research Evidence / Overview of Studies for Olfen/Olfen 100 SR

This section provides an overview of the types of research and studies that have examined Olfen/Olfen 100 SR (diclofenac), focusing on what was studied and where the evidence has limitations, without giving any medical advice.

---

Evidence for Use in Osteoarthritis (OA)

Research exploring Diclofenac (Olfen/Olfen 100 SR) in the context of conditions where daily activities may be restricted, such as osteoarthritis, was primarily involved in short-term to intermediate-term Randomized Controlled Trials (RCTs). The primary focus of these trials was on outcomes related to patient-reported assessments of pain intensity and functional measures of daily activity.

Studies report how symptoms evolved in the observed populations, with findings describing patterns observed over the typical follow-up period of a few weeks up to a few months. What remains uncertain is the full picture of long-term changes. Evidence is limited when examining outcomes that go beyond the one-year mark.

---

Evidence for Use in Rheumatoid Arthritis (RA) and Ankylosing Spondylitis (AS)

Research examined the use of Olfen/Olfen 100 SR in rheumatoid arthritis, a condition involving cycles of stability and flare-ups, and in ankylosing spondylitis. This evidence base includes short-term RCTs and larger observational studies. The studies explored outcomes related to systemic or functional imbalance, such as joint tenderness and disease activity scores.

In the longer observational studies, research describes the monitoring of safety outcomes, such as cardiovascular events, observed in these patient cohorts. Comparative evidence is lacking for how this specific formulation stands up against all newer, targeted therapies used in RA, and the total number of dedicated studies for AS is smaller compared to OA research.

---

Long-Term Studies and Uncertainty

For Olfen/Olfen 100 SR, dedicated long-term efficacy RCTs are not fully established. Observational studies, primarily used to monitor safety, were not structured to evaluate persistence of measured outcomes over extended periods. Data for certain groups, such as specific pediatric populations or patients with certain stages of kidney impairment, remain insufficient, meaning subgroup findings are uncertain in many cases.

Key Studies & References American Geriatrics Society 2019 Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults (Used to inform special population limitations)

Common questions about Olfen/Olfen 100 SR (FAQ)

Q: What is Olfen/Olfen 100 SR?

A: Olfen/Olfen 100 SR contains diclofenac, which belongs to a class of medications called Nonsteroidal Anti-Inflammatory Drugs (NSAIDs). It is studied for its action in managing certain types of discomfort and swelling.

Q: How might Olfen/Olfen 100 SR affect discomfort?

A: Research on diclofenac suggests that it works by influencing the body's production of substances that contribute to discomfort and swelling. Clinical studies indicate that it may offer relief from acute and chronic discomfort associated with various conditions.

Q: What is the difference between Olfen and Olfen 100 SR?

A: The difference relates to the formulation. Olfen is typically formulated for standard release, while Olfen 100 SR is a sustained-release formulation. This means the 100 SR formulation is designed to release the ingredient slowly over a period of time, which may result in different administration schedules as determined by a healthcare provider.

Q: Can Olfen/Olfen 100 SR cause stomach issues?

A: Like other NSAIDs, diclofenac carries a known risk of gastrointestinal side effects. These may include stomach upset or, less commonly, more serious issues. The risk may increase with higher doses or prolonged use. A healthcare provider can discuss individual risk factors.

Q: Is Olfen/Olfen 100 SR suitable for everyone?

A: No. This medication is not appropriate for all individuals. Contraindications or precautions exist for people with certain health conditions, particularly those related to the heart, stomach, or kidneys. It is essential to consult a healthcare professional to determine if this medication is suitable for your specific health situation.

Storage and Disposal of Olfen/Olfen 100 SR

Storage of Olfen/Olfen 100 SR (Diclofenac Sodium) must adhere strictly to labeled requirements to maintain product integrity.

---

Official Storage Requirements

• Temperature: Store the medicine at controlled room temperature, typically not above 25°C (77°F) or 30 C depending on the formulation.
• Protection: The product must be stored in the original packaging to protect it from light and moisture.
• Safety: A primary mandate is to keep the medicine out of the sight and reach of children.
• Stability: The medicine should not be used after the expiry date printed on the carton.

---

Disposal Instructions

Unused or expired Olfen/Olfen 100 SR must not be disposed of in wastewater or mixed with household trash. Disposal must be performed according to local regulations for pharmaceutical waste handling.